Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 89

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 89
---
 7, 2023 and 1/48th of the shares of our common stock underlying the option on each monthly anniversary thereafter, subject to each such holder continuing to provide services to the Company through each such vesting date. (4) This stock option fully vests on March 6, 2027, and vests at a rate of 25% of the shares of our common stock underlying the option on March 6, 2024 and 1/48th of the shares of our common stock underlying the option on each monthly anniversary thereafter, subject to such holder continuing to provide services to the Company through each such vesting date. (5) This stock option fully vests on March 1, 2028, and vests at a rate of 25% of the shares of our common stock underlying the option on March 1, 2025 and 1/48th of the shares of our common stock underlying the option on each monthly anniversary thereafter, subject to such holder continuing to provide services to the Company through each such vesting date. (6) This stock option fully vests on December 31, 2026, and vests at a rate of 25% of the shares of our common stock underlying the option on December 31, 2023 and 1/48th of the shares of our common stock underlying the option on each monthly anniversary thereafter, subject to Mr. Arif continuing to provide services to the Company through each such vesting date. (7) The RSUs fully vested on March 3, 2025, with 25% of the shares vesting on each anniversary of the date of grant, subject to each such holder continuing to provide services to the Company through each such vesting date. (8) The RSUs fully vest on March 7, 2026, with 25% of the shares vesting on each anniversary of the date of grant, subject to each such holder continuing to provide services to the Company through each such vesting date. (9) The 5,500 PSUs granted on March 7, 2022, were earned as of the second quarter of 2024 based upon the achievement of Elevidys approval, as described in the "2022 Equity Incentive Compensation" section of our 2022 proxy statement. The earned PSUs fully vested on March 7, 2025. (10) The 4,500 RSUs fully vest on March 6, 2027, with 25%